Company intelligence / Profile preview

Forlong Biotechnology

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Lead program FL115 (an IL-15 superagonist) demonstrated good safety and initial efficacy as monotherapy and in combination with checkpoint inhibitors in Phase 1 studies for advanced solid tumors in the US and China, including achieving partial responses as monotherapy. Combo studies with anti-PD-1 and with BCG in NMIBC currently advancing to Phase 2. Preclinical pipeline assets (FL116, FL117, FL118) show tumor-killing activity in resistant models.

Therapeutic areas: Oncology
Modalities: ProteinRecombinant proteinFusion proteinAntibodyCytokineBiologic
Industry: Biotech

Drug pipeline

6 assets

FL-115

5 more assets in the full pipeline.

Request access →

Partnerships

Shell BioTechHenliusThird-party licensee (unnamed, China IND for Fbody fusion protein)

Beyond the preview

Go deeper on Forlong Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forlong Biotechnology.

Explore the full profile